ANTHRACYCLINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS

Tech ID: 33816 / UC Case 2025-051-0

PATENT STATUS

Patent Pending

BRIEF DESCRIPTION

Current treatments for cancer often fail due to drug resistance, a significant challenge in oncology. Existing anthracycline derivatives, while effective, can also lead to severe side effects, such as cardiotoxicity, which limits their therapeutic use. This innovative technology, developed by UC Berkeley researchers, addresses these critical problems by creating novel anthracycline derivatives with improved efficacy against chemoresistant cancers and reduced cardiotoxic effects. The new compounds work by overcoming the mechanisms of drug resistance and offering a more tolerable and effective treatment option for patients.

SUGGESTED USES

» Treatment of various types of cancer, including solid tumors and leukemias

» Targeting chemoresistant cancer types that do not respond to conventional therapies

» Use as a standalone chemotherapy agent or in combination with other drugs to enhance therapeutic outcomes

ADVANTAGES

» Increased effectiveness against chemoresistant cancer cells

» Reduced cardiotoxic side effects compared to traditional anthracyclines

» Potential for use in a broader range of patients who cannot tolerate existing treatments

» Improved therapeutic index, allowing for more aggressive and successful treatment regimens

RELATED MATERIALS

ADDITIONAL TECHNOLOGIES BY THESE INVENTORS

▶ Compositions and Methods for Driving Cell Competition to Kill Cancer Cells

CONTACT

Laleh Shayesteh
lalehs@berkeley.edu
tel: 510-642-4537.

INTRODUCING
UC TechAlerts
New technology matches delivered to your email at your preferred schedule
SEARCH ▸ SAVE SEARCH
Learn More

INVENTORS

» Braverman, Jonathan

OTHER INFORMATION

CATEGORIZED AS

» **Biotechnology**

» Health

RELATED CASES

2025-051-0

University of California, Berkeley Office of Technology Licensing
2150 Shattuck Avenue, Suite 510, Berkeley,CA 94704
Tel: 510.643.7201 | Fax: 510.642.4566
https://ipira.berkeley.edu/ | otl-feedback@lists.berkeley.edu
© 2025, The Regents of the University of California
Terms of use | Privacy Notice